John Bencich
2017
In 2017, John Bencich earned a total compensation of $1.1M as Executive Vice President and Chief Financial Officer and Chief Operating Officer at OncoGenex Pharmaceuticals, a 213% increase compared to previous year.
Compensation breakdown
| Bonus | $75,000 |
|---|---|
| Option Awards | $574,696 |
| Salary | $335,833 |
| Stock Awards | $158,372 |
| Total | $1,143,901 |
Bencich received $574.7K in option awards, accounting for 50% of the total pay in 2017.
Bencich also received $75K in bonus, $335.8K in salary and $158.4K in stock awards.
Rankings
In 2017, John Bencich's compensation ranked 8,334th out of 14,666 executives tracked by ExecPay. In other words, Bencich earned more than 43.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,334 out of 14,666 | 43rd |
Division Manufacturing | 3,161 out of 5,772 | 45th |
Major group Chemicals And Allied Products | 1,047 out of 2,075 | 50th |
Industry group Drugs | 824 out of 1,731 | 52nd |
Industry In Vitro and In Vivo Diagnostic Substances | 31 out of 72 | 57th |
Source: SEC filing on April 19, 2018.
Bencich's colleagues
We found four more compensation records of executives who worked with John Bencich at OncoGenex Pharmaceuticals in 2017.
News
OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
April 28, 2023
OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
April 21, 2022
OncoGenex Pharmaceuticals CEO Richard Stewart's 2020 pay jumps 30% to $1M
March 30, 2021
OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
April 2, 2020
OncoGenex Pharmaceuticals CEO Richard Stewart's 2018 pay jumps 423% to $1.1M
March 28, 2019